Last updated today
Checkpoint Therapeutics, Inc. (Checkpoint) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In addition, Checkpoint is currently evaluating its lead antibody product candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in a Phase 1 clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers. Checkpoint plans to develop CK-301 as a treatment for patients with NSCLC and other solid tumors. Checkpoint is a majority-controlled subsidiary of Fortress Biotech, Inc., and is headquartered in New York City.
Last updated today
Coming soon.
No recent security news.
More security reports
Cybersecurity & Risk Management Library
The ultimate guide to attack surface and third-party risk management – actionable advice for security teams, managers, and executives.
Breaches
Security research and global news about data breaches.
Explore resources
Third-party risk management
Articles, news, and research on third-party risk management.
Explore resources
Attack Surface Management
Articles, news, and research on attack surface management.
Explore resources
Cybersecurity
Articles, news, and research on cybersecurity.
Explore resources
Leader in Third Party & Supplier Risk Management Software
See how UpGuard shapes up against other platforms in the market.
"This is some text inside of a div block."
Free instant security score
How secure is your organization?
Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
- Instant insights you can act on immediately
- Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Want a full vendor security report for this company?
Start your free trial and unlock real-time insights to identify and assess vendor risks.